anti glp 1 drugs FDA says that the GLP-1 shortage is over GLP-1 drugs are often misunderstood.

especially since the intrinsic hypoglycaemia risk of DPP-4 inhibitors is very low

Schedule a consultation with NTX Weight Loss and discover how semaglutide and tirzepatide can help you achieve your goals

Factors independent of glycaemic and weight loss effects have also been suggested to affect the cardiovascular protective effects of GLP-1RAs

La reputacin es un factor determinante: revisar certificaciones, auditoras independientes y la transparencia en la publicacin de probabilidades incrementa la confianza

The bottom line: Our findings suggest that GLP-1RA and SGLT2i (and especially SGLT2i with the lowest number needed to treat (NNT) for nearly all study outcomes) may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate risk for CVD, building on and consistent with existing RCT evidence in the high-risk population. This report highlights potential preference for GLP-1 drugs as a first-line treatment for Type 2 diabetes related to its cardioprotective effect